Tomoki Tamura

Dr. Tomoki Tamura

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
TTTomoki Tamura
Tomoki Tamura
EAEtsuko Akimoto
Etsuko Akimoto
CMChiaki Matsumoto
Chiaki Matsumoto
SMSyunta Mori
Syunta Mori
TNTatuya Nishi
Tatuya Nishi
SKSyouichi Kuyama
Syouichi Kuyama

8 February 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KMKohei Miyake
Kohei Miyake
SSSatoru Senoo
Satoru Senoo
RSRitsuya Shiiba
Ritsuya Shiiba
JIJunko Itano
Junko Itano
GKGoro Kimura
Goro Kimura
O(Okayama Respiratory Disease Study Group (ORDSG)
Okayama Respiratory Disease Study Group (ORDSG)
Objective: Long-term steroid use increases the risk of developing Pneumocystis pneumonia (PcP), but there are limited reports on the relation of long-term steroid and PcP mortality. Methods: Retrospective multicenter study to identify risk factors for PcP mortality, including average steroid dose before the first visit for PcP in non-human immunodeficiency virus (HIV)-PcP patients. We generated receiver operating characteristic (ROC) curves for 90-day all-cause mortality and the mean daily steroid dose per unit body weight in the preceding 10 to 90 days in 10-day increments. Patients were dichotomized by 90-day mortality and propensity score-based stabilized inverse probability of treatment weighting (IPTW) adjusted covariates of age, sex, and underlying disease. Multivariate analysis with logistic regression assessed whether long-term corticosteroid use affected outcome. Results: Of 133 patients with non-HIV-PcP, 37 died within 90 days of initial diagnosis. The area under the ROC curve for 1–40 days was highest, and the optimal cutoff point of median adjunctive corticosteroid dosage was 0.34 mg/kg/day. Past steroid dose, underlying interstitial lung disease and emphysema, lower serum albumin and lower lymphocyte count, higher lactate dehydrogenase, use of therapeutic pentamidine and therapeutic high-dose steroids were all significantly associated with mortality. Underlying autoimmune disease, past immunosuppressant use, and a longer time from onset to start of treatment, were associated lower mortality. Logistic regression analysis after adjusting for age, sex, and underlying disease with IPTW revealed that steroid dose 1–40 days before the first visit for PcP (per 0.1 mg/kg/day increment, odds ratio 1.36 [95% confidence interval = 1.16–1.66], P<0.001), low lymphocyte counts, and high lactate dehydrogenase revel were independent mortality risk factor, while respiratory failure, early steroid, and sulfamethoxazole/trimethoprim for PcP treatment did not. Conclusion: A steroid dose before PcP onset was strongly associated with 90-day mortality in non-HIV-PcP patients, emphasizing the importance of appropriate prophylaxis especially in this population.

1 January 2021 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
KKKeita Kawakado
Keita Kawakado
TYTakayuki Yabuki
Takayuki Yabuki
TNTatsuya Nishi
Tatsuya Nishi
MNMasamoto Nakanishi
Masamoto Nakanishi
GMGo Makimoto
Go Makimoto
SKShoichi Kuyama
Shoichi Kuyama
Cases of inferior phrenic artery-to-pulmonary artery fistulas and those complicated by massive hemoptysis have been rarely reported. A 38-year-old man presented to our hospital with a chief complaint of coughing. Computed tomography (CT) revealed a nodule in the left lower lobe, and contrast-enhanced CT showed inflow of contrast medium into the nodule. CT angiography detected an aneurysm associated with a left inferior phrenic artery-to-left pulmonary artery fistula. Transcatheter arterial embolization (TAE) was performed to prevent hemoptysis. Hemoptysis did not occur during the 2-year follow-up. We report a rare case of asymptomatic aneurysm associated with a left inferior phrenic artery-to-left pulmonary artery fistula, which was successfully treated using TAE to prevent hemoptysis.

28 December 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
TTTomoki Tamura
Tomoki Tamura
KNKiichiro Ninomiya
Kiichiro Ninomiya
TKToshio Kubo
Toshio Kubo
SKShoichi Kuyama
Shoichi Kuyama
STSayaka Tachibana
Sayaka Tachibana
KKKatsuyuki Kiura
Katsuyuki Kiura
Background: Since 2020, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become prevalent worldwide. In severe cases, the case fatality rate is high, and vaccine prevention is important. This study evaluated the safety of receiving SARS‐CoV‐2 vaccine in patients with advanced lung cancer receiving anticancer therapy.Methods: We prospectively enrolled patients receiving anticancer drugs for advanced lung cancer who planned to receive SARS‐CoV‐2 vaccination. Early adverse events within 7 days of vaccine injection were evaluated using patient‐reported surveys. The chi‐square test and multivariate logistic regression analyses were used.Results: Among 120 patients receiving lung cancer treatment, 73 were men; the mean age of the patients was 73.5 years. The treatments received for lung cancer at the time of the first vaccine injection were chemotherapy, ICIs, combined chemotherapy and ICIs, and targeted therapies, including tyrosine kinase inhibitors, in 30, 28, 17, and 45 patients, respectively. All patients received SARS‐CoV‐2 messenger RNA (mRNA) vaccine. After the second mRNA vaccine dose, 15.4% of patients had fever of 38°C (95% confidence interval: 9.34%–23.2%); this rate was slightly higher than that for healthy participants at the time of the BNT162b2 trial. Patients treated with cytotoxic anticancer drugs tended to have high fever. In the multivariate analyses, male sex was associated with higher fever frequencies. However, there were no serious early adverse events due to vaccination.Conclusions: Anti‐SARS‐CoV‐2 mRNA vaccination tends to be safe, but fever following vaccination tends to be more common among patients undergoing lung cancer treatment than among healthy individuals.

14 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TNTomoka Nishimura
Tomoka Nishimura
EIEiki Ichihara
Eiki Ichihara
TYToshihide Yokoyama
Toshihide Yokoyama
KIKoji Inoue
Koji Inoue
TTTomoki Tamura
Tomoki Tamura
KKKatsuyuki Kiura
Katsuyuki Kiura
Objectives: Combined immune checkpoint inhibitor (ICI) therapy and chemotherapy has become the standard treatment for advanced non-small-cell lung cancer (NSCLC). Pleural effusion (PE) is associated with poor outcomes among patients with NSCLC undergoing chemotherapy. However, minimal data exists on PE for patients undergoing combined ICI and chemotherapy. Therefore, we investigated how PE affects survival outcomes in patients with NSCLC undergoing this combined therapy. Methods: We identified patients with advanced NSCLC undergoing chemotherapy and ICI therapy from the Okayama Lung Cancer Study Group–Immune Chemotherapy Database (OLCSG–ICD) between December 2018 and December 2020; the OLCSG–ICD includes the clinical data of patients with advanced NSCLC from 13 institutions. Then, we analyzed the treatment outcomes based on the presence of PE. Results: We identified 478 patients who underwent combined ICI therapy and chemotherapy; 357 patients did not have PE, and 121 patients did have PE. Patients with PE had significantly shorter progression-free survival (PFS) and overall survival (OS) than those without PE (median PFS: 6.2 months versus 9.1 months; p < 0.001; median OS: 16.4 months versus 27.7 months; p < 0.001). The negative effect of PE differed based on the patient’s programmed cell death-ligand 1 (PD-L1) expression status; with the effect being more evident in patients with high PD-L1 expression. In addition, PFS and OS did not differ between patients who did and did not undergo bevacizumab treatment; thus, bevacizumab-containing regimens did not improve the survival outcomes for patients with PE. Conclusion: PE is associated with poor outcomes among patients with NSCLC undergoing combined ICI therapy and chemotherapy.

28 April 2021 in In Vivo
Verified
Journal Article
Closed access
PDF file
TTTomoki Tamura
Tomoki Tamura
KKKeita Kawakado
Keita Kawakado
GMGo Makimoto
Go Makimoto
MNMasamoto Nakanishi
Masamoto Nakanishi
SKShoichi Kuyama
Shoichi Kuyama
Background: The guidelines on pharmacotherapy for cancer-related pain advocate active measures against the adverse effects of opioids to increase adherence to medication. However, preventative therapy for the management of nausea and vomiting has not been specified. This study aimed to verify the effects of prophylactic anti-emetics in preventing opioid-induced nausea and vomiting. Patients and Methods: We conducted a retrospective analysis of cases at our hospital in which oral opioids or patches were initiated for the management of pain due to malignant tumours from January 2017 to September 2019. Results: Strong opioids were initiated for 349 patients; of these, data for 298 patients were analysed. A total of 193 patients were on anti-emetic prophylaxis. We found that the group that did not receive anti-emetic prophylaxis was significantly more likely to be prescribed an additional anti-emetic. Conclusion: Prophylactic administration of anti-emetics at the time of initiating opioid analgesics may reduce gastrointestinal toxicity.